This invention is related to compounds of general formula (I) wherein X is oxygen or sulphur or a NR.sup.7 group; R.sup.1 is C.sub.3-C.sub.8 alkyl, or C.sub.1-C.sub.8 alkyl substituted by phenoxy or phenyl, both phenoxy or phenyl being optionally substituted by one or more fluoro, chloro, trifluoromethyl, C.sub.1-C.sub.6 alkyl, hydroxyl, C.sub.1-C.sub.6 alkoxy; R.sup.2, R.sup.3 are independently hydrogen, C.sub.1-C.sub.6 alkyl, halogen, trifluoromethyl, hydroxy or C.sub.1-C.sub.6 alkoxy; R.sup.4 is hydrogen, C.sub.1-C.sub.8 alkyl; R.sup.5, R.sup.6 are independently hydrogen, C.sub.1-C.sub.3 alkyl, optionally substituted by hydroxy or phenyl; R.sup.7 is hydrogen or straight or branched C.sub.1-C.sub.3 alkyl; Het is a five to seven membered, saturated or unsaturated heteromonocyclic or an eight to ten membered, saturated or unsaturated heterobicyclic group, containing one or more heteroatoms chosen independently from nitrogen, oxygen and sulphur, said mono- or bicyclic groups being optionally substituted by C.sub.1-C.sub.6alkyl, halogen, hydroxyl or C.sub.1-C.sub.6 alkoxy; and the pharmaceutically acceptable salts or prodrug thereof, that are active as sodium and/or calcium channel modulators and/or as selective MAO-B inhibitors and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role. ##STR00001##